Harlan Waksal

Harlan Waksal is a declared insider at 4 companies (chief executive); the most frequent names are Kadmon Holdings, Inc., Eloxx Pharmaceuticals, Inc. and Lyra Therapeutics, Inc. In total, 23 filings cover trades dated from 29 July 2009 to 20 July 2026.

On the market, this insider has only ever bought: 13 purchases, €1.3M in total. No amount is published for 3 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 6 share grants.

Half of the purchases are above €27k and half below. Of 8 purchases, 5 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The latest filing, published on 29 July 2026, reports a transaction in Freenome, Inc. The latest purchase dates back some time: it was published 1,076 days ago, on 13 November 2023. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.